In concert with these findings, our study showed that ETS2 was upregulated in IBD and higher ETS2 expression predicted resistance to infliximab (α-TNFα) treatment for IBD (Supplementary Fig. 4C, D). Here, TNF is linked to inflammatory bowel disease.